bortezomib
(Bortezomib)Ingenus Pharmaceuticals, LLC
Usage: Bortezomib for Injection is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.
11 results
bortezomib
(Bortezomib)Novadoz Pharmaceuticals LLCUsage: Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.bortezomib
(BORTEZOMIB)Hospira, Inc.Usage: Bortezomib for Injection is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.bortezomib
(bortezomib)Hikma Pharmaceuticals USA Inc.Usage: Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.bortezomib
(Bortezomib)NorthStar RxLLCUsage: Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.boruzu
(Bortezomib)Amneal Pharmaceuticals LLCUsage: BORUZU is indicated for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.jaypirca
(pirtobrutinib)Eli Lilly and CompanyUsage: JAYPIRCA® is indicated for adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two systemic therapies, including a BTK inhibitor. It is also indicated for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after two prior therapies, including a BTK and a BCL-2 inhibitor.lenalidomide
(Lenalidomide)Biocon Pharma Inc.Usage: Lenalidomide is indicated for treating multiple myeloma (MM) in combination with dexamethasone, as maintenance therapy post-autologous stem cell transplantation, and for transfusion-dependent anemia due to myelodysplastic syndromes. It's also used for relapsed mantle cell lymphoma and in combination with rituximab for follicular and marginal zone lymphomas.lenalidomide
(lenalidomide)Cipla USA Inc.Usage: Lenalidomide capsules are indicated for treating adult patients with multiple myeloma (in combination with dexamethasone or as maintenance therapy post-transplant), myelodysplastic syndromes, mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma (with rituximab). Not recommended for chronic lymphocytic leukemia outside clinical trials.revlimid
(Lenalidomide)Celgene CorporationUsage: REVLIMID is indicated for adult patients with multiple myeloma (MM), myelodysplastic syndromes (MDS), mantle cell lymphoma (MCL), follicular lymphoma (FL), and marginal zone lymphoma (MZL). It is used in combination with dexamethasone, rituximab products, or as maintenance therapy post-transplant. Not recommended for chronic lymphocytic leukemia (CLL).